Evidence map›Paper›PMID 22358377›Full record

ReviewDer Urologe. Ausg. A2012

[Value of positron emission tomography in urological neoplasms: more form than substance?].

J Müller, M Schrader, A J Schrader, M Höpfner, F Zengerling

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Application of (18)F-FDG PET/CT imaging in diagnosing bladder tumor metastasis lesions.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J MüllerKlinik für Urologie, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075 Ulm, Deutschland.
M Schrader
A J Schrader
M Höpfner
F Zengerling
University Hospital Ulm · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography/computed tomography (PET/CT) is widely used for imaging urological neoplasms. This overview should help the urologist actively involved in oncology to assess the value of PET or PET/CT in each tumor entity. Besides prostate, testicular, renal, and bladder cancer less common urological malignancies like penile carcinoma and retroperitoneal masses are discussed. Differences in using PET/CT for primary diagnosis, staging, or restaging are outlined separately. Appropriate indications for the use in clinical practice are cited.

Indexed as

Image EnhancementImage Interpretation, Computer-AssistedMultimodal ImagingPositron-Emission TomographyTomography, X-Ray ComputedDisease ProgressionHumansLymphatic MetastasisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm, ResidualNeoplasm StagingSensitivity and SpecificityUrologic Neoplasms

Identifiers

PMID22358377
OpenAlexW164310004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.